Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
200 shown of 2,656 total abstracts
  1. Abstract 14562026-09-04 · 21:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-991 study)
    S. Modi, S. Peters, M.C. Garassino, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 95382026-09-02 · 19:30 CT · Hall B1
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    M. Reck, T. Mok, G. Curigliano · University of Chicago
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  3. Abstract 46602026-09-04 · 14:00 CT · E450
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-915
    S. Tolaney, N. Rizvi, J. Brahmer · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  4. Abstract 45542026-09-01 · 20:15 CT · Arie Crown Theater
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    F. Andre, E. Winer, G. Curigliano, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  5. Abstract 17762026-09-03 · 14:00 CT · S406
    DESTINY-Breast-113: Enhertu (trastuzumab deruxtecan) 1L in HR+ breast cancer
    L. Paz-Ares, G. Curigliano, F. Andre, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract 60422026-09-04 · 13:15 CT · E450
    OlympiA-731: Lynparza (olaparib) adjuvant in ovarian
    S. Peters, E. Winer · Massachusetts General Hospital
    Poster SessionGynecologic Cancer📄🖼️
  7. Abstract 96612026-09-04 · 21:30 CT · E450
    Quality of life outcomes with Imfinzi in patients with NSCLC
    S. Modi, G. Curigliano, E. Winer, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  8. Abstract 12952026-09-03 · 16:00 CT · Arie Crown Theater
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    C. Saura, S. Antonia, M. Krop, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract 13272026-09-04 · 18:30 CT · S100A
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    M. Krop, S. Modi · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract 17132026-09-02 · 18:45 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-137
    A. Spira, P. Schmid, H. Borghaei, et al. · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  11. Abstract 11202026-09-03 · 16:15 CT · E450
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    T. Mok, S. Peters · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract 18722026-09-02 · 19:00 CT · S100A
    MONARCH-129: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    T. Mok, E. Winer · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract 99952026-09-01 · 16:30 CT · S100A
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    C. Robert, C. Saura, T. Mok · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  14. Abstract 99112026-09-04 · 15:00 CT · S100A
    Long-term follow-up of Imfinzi 2L for NSCLC: PACIFIC-871
    F. Andre, R. Herbst, H. Borghaei, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  15. Abstract 11782026-09-02 · 13:15 CT · E450
    PALOMA-573: Ibrance (palbociclib) 2L in HR+ breast cancer
    A. Spira, J. Brahmer, H. Borghaei, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract TPS80152026-09-02 · 15:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-362 study)
    S. Tolaney, G. Curigliano, L. Paz-Ares · Vall d'Hebron Institute of Oncology
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  17. Abstract 46882026-09-05 · 15:15 CT · S406
    Long-term follow-up of Tecentriq 1L for HCC: IMpower-591
    J. Brahmer, M.C. Garassino, R. Herbst, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  18. Abstract 94002026-09-05 · 18:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-893 study)
    J. Brahmer, S. Peters, G. Curigliano, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  19. Abstract 10452026-09-03 · 21:30 CT · S100A
    MONALEESA-441: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    H. Borghaei, C. Saura, E. Winer, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  20. Abstract 96292026-09-03 · 19:30 CT · E450
    Long-term follow-up of Opdivo 3L+ for NSCLC: CheckMate-439
    A. Spira, E. Winer, F. Andre, et al. · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  21. Abstract LBA4020LBA2026-09-05 · 21:00 CT · S406
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-823 study)
    S. Peters, M. Krop · Johns Hopkins Kimmel Cancer Center
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  22. Abstract 97652026-09-01 · 18:30 CT · E450
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    F. Andre, S. Tolaney, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  23. Abstract 44672026-09-05 · 20:15 CT · S406
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-850
    S. Antonia, H. Rugo, E. Winer, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  24. Abstract 16682026-09-05 · 19:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-875 study)
    S. Modi, P. Schmid · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  25. Abstract 97612026-09-02 · 13:00 CT · Hall B1
    FLAURA-749: Tagrisso (osimertinib) 3L+ in NSCLC
    S. Peters, M. Reck · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  26. Abstract TPS80252026-09-03 · 13:30 CT · S100A
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    M.C. Garassino, S. Tolaney, S. Antonia · Karolinska Institute
    Trials in Progress Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  27. Abstract 57652026-09-02 · 18:30 CT · Hall B1
    Quality of life outcomes with Lynparza in patients with prostate
    F. Andre, C. Robert, H. Borghaei, et al. · Royal Marsden Hospital
    Clinical Science SymposiumGenitourinary Cancer—Prostate📄🖼️
  28. Abstract 17752026-09-01 · 20:15 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-406
    N. Rizvi, F. Andre, E. Winer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract e120282026-09-01 · 13:30 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-431
    R. Herbst, J. Cortes, M.C. Garassino · Cleveland Clinic
    Publication OnlyLung Cancer—Non-Small Cell Metastatic📄🖼️
  30. Abstract 90242026-09-05 · 16:15 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-602
    M. Krop, C. Robert · Karolinska Institute
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  31. Abstract 96502026-09-03 · 19:15 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi neoadjuvant for SCLC: PACIFIC-70
    T. Mok, R. Herbst, C. Saura, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  32. Abstract 15342026-09-03 · 18:00 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-42 study)
    C. Robert, R. Herbst, S. Antonia · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  33. Abstract 96192026-09-03 · 16:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-561 study)
    T. Mok, L. Paz-Ares, A. Spira, et al. · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  34. Abstract 104562026-09-03 · 15:15 CT · E450
    KEYNOTE-947: Keytruda (pembrolizumab) maintenance in metastatic melanoma
    J. Cortes, S. Peters, S. Antonia, et al. · National Cancer Center Japan
    Poster SessionMelanoma📄🖼️
  35. Abstract 45732026-09-04 · 21:30 CT · S406
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-923 study)
    F. Andre, H. Borghaei, G. Curigliano, et al. · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  36. Abstract 43352026-09-03 · 19:30 CT · S100A
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    M. Reck, S. Antonia, S. Tolaney, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  37. Abstract 59222026-09-01 · 18:30 CT · S406
    Quality of life outcomes with Lynparza in patients with ovarian
    A. Spira, S. Tolaney, R. Herbst · Dana-Farber Cancer Institute
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  38. Abstract 98052026-09-05 · 21:45 CT · Hall B1
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    S. Antonia, M. Krop, M. Reck, et al. · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  39. Abstract 16842026-09-04 · 21:00 CT · Hall B1
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    H. Rugo, J. Brahmer, G. Curigliano, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  40. Abstract 18122026-09-01 · 16:00 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-181
    H. Borghaei, M. Reck, T. Mok, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  41. Abstract 15792026-09-04 · 14:15 CT · Arie Crown Theater
    ASCENT-749: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    H. Rugo, J. Brahmer, S. Peters · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  42. Abstract TPS80412026-09-02 · 19:00 CT · E450
    CheckMate-374: Opdivo (nivolumab) 3L+ in NSCLC
    J. Brahmer, F. Andre, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Trials in Progress Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  43. Abstract 98892026-09-05 · 19:15 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-265 study)
    J. Cortes, N. Rizvi, C. Robert, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  44. Abstract 11612026-09-04 · 14:30 CT · S100A
    PALOMA-963: Ibrance (palbociclib) maintenance in HR+ breast cancer
    S. Modi, M.C. Garassino, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  45. Abstract 68582026-09-01 · 15:30 CT · S406
    KEYNOTE-734: Keytruda (pembrolizumab) adjuvant in RCC
    L. Paz-Ares, M.C. Garassino, J. Brahmer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  46. Abstract 96542026-09-01 · 19:45 CT · Hall B1
    FLAURA-467: Tagrisso (osimertinib) adjuvant in NSCLC
    M. Krop, M. Reck · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  47. Abstract 14132026-09-04 · 13:00 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-792
    J. Brahmer, L. Paz-Ares, G. Curigliano, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  48. Abstract 11132026-09-04 · 21:45 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-41
    T. Mok, S. Tolaney · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  49. Abstract 16322026-09-04 · 13:15 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-708
    C. Robert, G. Curigliano, S. Tolaney, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  50. Abstract 16682026-09-02 · 18:00 CT · Hall B1
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-570
    C. Saura, H. Rugo, F. Andre · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  51. Abstract TPS80502026-09-04 · 15:00 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-186 study)
    S. Peters, H. Rugo · Princess Margaret Cancer Centre
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  52. Abstract 94062026-09-03 · 16:45 CT · E450
    PACIFIC-83: Imfinzi (durvalumab) 1L in SCLC
    N. Rizvi, R. Herbst · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  53. Abstract 100982026-09-05 · 21:15 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
    S. Peters, A. Spira · MD Anderson Cancer Center
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  54. Abstract 16662026-09-04 · 21:15 CT · E450
    ASCENT-27: Trodelvy (sacituzumab govitecan) adjuvant in TNBC
    L. Paz-Ares, P. Schmid · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  55. Abstract 15732026-09-02 · 14:45 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-364
    S. Peters, M.C. Garassino, M. Reck · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  56. Abstract 91952026-09-02 · 13:45 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-927 study)
    M. Krop, S. Antonia, R. Herbst, et al. · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  57. Abstract 93222026-09-01 · 14:15 CT · Arie Crown Theater
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    F. Andre, L. Paz-Ares · University of Chicago
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  58. Abstract 12752026-09-04 · 21:15 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-827
    E. Winer, F. Andre, A. Spira · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  59. Abstract 43372026-09-05 · 16:30 CT · S406
    EV-874: Padcev (enfortumab vedotin) maintenance in urothelial carcinoma
    H. Rugo, S. Peters, J. Brahmer · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  60. Abstract LBA4059LBA2026-09-05 · 20:30 CT · E450
    Biomarker subgroup analysis of Lynparza in ovarian (the OlympiA-436 study)
    T. Mok, J. Cortes, M.C. Garassino · Princess Margaret Cancer Centre
    Plenary SessionGynecologic Cancer📄🖼️
  61. Abstract 15202026-09-03 · 15:45 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with TNBC
    S. Modi, P. Schmid, C. Robert, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  62. Abstract 19302026-09-05 · 13:00 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-742
    N. Rizvi, P. Schmid, S. Antonia · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  63. Abstract 56452026-09-01 · 13:30 CT · Hall B1
    Real-world effectiveness of Lynparza vs standard of care in ovarian
    G. Curigliano, C. Saura, F. Andre · Chinese University of Hong Kong
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  64. Abstract 56212026-09-02 · 15:00 CT · S100A
    Long-term follow-up of Lynparza 2L for ovarian: OlympiA-257
    S. Peters, H. Rugo · Memorial Sloan Kettering Cancer Center
    Poster SessionGynecologic Cancer📄🖼️
  65. Abstract 100452026-09-01 · 14:00 CT · Hall B1
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    M. Reck, T. Mok · Princess Margaret Cancer Centre
    Poster Discussion SessionMelanoma📄🖼️
  66. Abstract e120652026-09-05 · 14:15 CT · Arie Crown Theater
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    C. Saura, S. Antonia, R. Herbst · Stanford Cancer Institute
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  67. Abstract 96882026-09-04 · 16:00 CT · E450
    PACIFIC-198: Imfinzi (durvalumab) adjuvant in SCLC
    E. Winer, C. Saura · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  68. Abstract 16052026-09-04 · 20:00 CT · S100A
    ASCENT-931: Trodelvy (sacituzumab govitecan) 1L in TNBC
    S. Antonia, E. Winer, L. Paz-Ares · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  69. Abstract 97472026-09-05 · 19:15 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in SCLC
    M. Reck, P. Schmid, M. Krop, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  70. Abstract 92542026-09-01 · 15:30 CT · S100A
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-466
    C. Saura, M.C. Garassino · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  71. Abstract 13012026-09-05 · 16:15 CT · E450
    Long-term follow-up of Tecentriq 1L for TNBC: IMpower-32
    L. Paz-Ares, N. Rizvi, G. Curigliano, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  72. Abstract 101182026-09-03 · 14:15 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    N. Rizvi, P. Schmid, H. Borghaei · Stanford Cancer Institute
    Poster SessionMelanoma📄🖼️
  73. Abstract 96032026-09-01 · 15:45 CT · Hall B1
    Long-term follow-up of Enhertu adjuvant for NSCLC: DESTINY-Breast-129
    M. Reck, H. Borghaei · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  74. Abstract 16652026-09-03 · 16:45 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-631
    S. Peters, J. Cortes, R. Herbst, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  75. Abstract 13952026-09-04 · 14:15 CT · Hall B1
    Long-term follow-up of Trodelvy maintenance for TNBC: ASCENT-244
    M. Krop, H. Borghaei · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  76. Abstract 16202026-09-05 · 21:45 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-878 study)
    T. Mok, F. Andre, J. Brahmer · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  77. Abstract 17782026-09-04 · 20:15 CT · Arie Crown Theater
    ASCENT-791: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    S. Peters, M. Krop, J. Brahmer · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  78. Abstract 10872026-09-02 · 18:15 CT · S100A
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    M. Krop, S. Modi, E. Winer · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  79. Abstract 15452026-09-01 · 19:30 CT · S406
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    C. Robert, P. Schmid · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  80. Abstract 44092026-09-03 · 19:45 CT · Arie Crown Theater
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    C. Saura, L. Paz-Ares, H. Rugo, et al. · National Cancer Center Japan
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  81. Abstract 10402026-09-03 · 15:15 CT · S100A
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    M. Krop, F. Andre, M.C. Garassino · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  82. Abstract 19732026-09-02 · 21:15 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-57
    C. Robert, P. Schmid, G. Curigliano · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  83. Abstract 19312026-09-05 · 19:00 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-227 study)
    T. Mok, H. Borghaei · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  84. Abstract LBA4083LBA2026-09-05 · 18:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-134 study)
    H. Borghaei, S. Antonia · Johns Hopkins Kimmel Cancer Center
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  85. Abstract 42002026-09-03 · 19:45 CT · S100A
    Long-term follow-up of Enhertu 3L+ for gastric: DESTINY-Breast-944
    R. Herbst, P. Schmid · University of Chicago
    Poster SessionGastrointestinal Cancer📄🖼️
  86. Abstract 49342026-09-03 · 19:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in HCC (the CheckMate-416 study)
    P. Schmid, M. Reck, E. Winer · Karolinska Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  87. Abstract 12342026-09-02 · 15:15 CT · S100A
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    S. Antonia, P. Schmid · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  88. Abstract 40282026-09-02 · 13:15 CT · E450
    Long-term follow-up of Padcev adjuvant for urothelial carcinoma: EV-710
    T. Mok, G. Curigliano, A. Spira, et al. · Peter MacCallum Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  89. Abstract 97262026-09-02 · 20:15 CT · Hall B1
    DESTINY-Breast-767: Enhertu (trastuzumab deruxtecan) 2L in NSCLC
    S. Antonia, S. Modi, T. Mok, et al. · Cleveland Clinic
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  90. Abstract e120892026-09-01 · 21:00 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-72
    S. Peters, H. Borghaei · Karolinska Institute
    Publication OnlyGenitourinary Cancer—Kidney/Bladder📄🖼️
  91. Abstract 46972026-09-03 · 14:00 CT · Hall B1
    Real-world effectiveness of Imfinzi vs standard of care in biliary tract
    M. Reck, T. Mok · Institut Gustave Roussy
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  92. Abstract e120912026-09-01 · 16:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-998 study)
    S. Peters, P. Schmid, H. Borghaei, et al. · Massachusetts General Hospital
    Publication OnlyLung Cancer—Small Cell📄🖼️
  93. Abstract 54922026-09-05 · 14:45 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 1L for prostate: OlympiA-503
    J. Cortes, G. Curigliano, A. Spira, et al. · Massachusetts General Hospital
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  94. Abstract 19972026-09-04 · 15:45 CT · Arie Crown Theater
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-514
    S. Modi, C. Saura · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  95. Abstract 17812026-09-05 · 21:00 CT · S406
    Long-term follow-up of Lynparza adjuvant for HR+ breast cancer: OlympiA-95
    S. Antonia, E. Winer, C. Robert, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  96. Abstract LBA4095LBA2026-09-05 · 21:15 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi adjuvant for biliary tract: PACIFIC-774
    T. Mok, H. Rugo, L. Paz-Ares, et al. · Peter MacCallum Cancer Centre
    Plenary SessionGastrointestinal Cancer📄🖼️
  97. Abstract 95172026-09-05 · 18:30 CT · Hall B1
    Quality of life outcomes with Opdivo in patients with NSCLC
    M.C. Garassino, C. Saura, F. Andre · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  98. Abstract 45572026-09-05 · 21:45 CT · S100A
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-391
    M. Reck, H. Rugo, C. Saura · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  99. Abstract 16952026-09-04 · 19:15 CT · Hall B1
    MONALEESA-667: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    J. Brahmer, H. Rugo · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  100. Abstract 40322026-09-01 · 13:00 CT · E450
    Long-term follow-up of Trodelvy adjuvant for urothelial carcinoma: ASCENT-76
    G. Curigliano, A. Spira, M.C. Garassino · Peter MacCallum Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  101. Abstract 44932026-09-05 · 13:00 CT · S100A
    Tecentriq plus chemotherapy in previously untreated HCC: updated analysis from IMpower-264
    J. Brahmer, H. Borghaei, C. Robert, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  102. Abstract 69342026-09-05 · 15:30 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-846
    S. Antonia, A. Spira, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  103. Abstract 17822026-09-01 · 19:45 CT · E450
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-860 study)
    M. Reck, S. Tolaney, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  104. Abstract 42812026-09-02 · 16:00 CT · S100A
    Quality of life outcomes with Enhertu in patients with gastric
    M. Krop, A. Spira, T. Mok · Memorial Sloan Kettering Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  105. Abstract 93892026-09-05 · 20:30 CT · E450
    Long-term follow-up of Opdivo neoadjuvant for NSCLC: CheckMate-525
    J. Cortes, M. Reck, F. Andre · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  106. Abstract 49862026-09-05 · 20:45 CT · Arie Crown Theater
    ASCENT-584: Trodelvy (sacituzumab govitecan) 3L+ in urothelial carcinoma
    C. Robert, E. Winer, S. Modi · Cleveland Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  107. Abstract 41352026-09-03 · 19:00 CT · E450
    DESTINY-Breast-687: Enhertu (trastuzumab deruxtecan) 2L in gastric
    L. Paz-Ares, C. Saura, S. Tolaney, et al. · Chinese University of Hong Kong
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  108. Abstract 67002026-09-01 · 16:30 CT · S100A
    Quality of life outcomes with Keytruda in patients with RCC
    C. Robert, S. Modi, M. Krop · Princess Margaret Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  109. Abstract 11302026-09-01 · 13:15 CT · Hall B1
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-200
    A. Spira, M. Reck, G. Curigliano · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  110. Abstract 10802026-09-01 · 13:45 CT · S406
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-558
    J. Brahmer, T. Mok, M. Reck, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  111. Abstract 64352026-09-03 · 18:15 CT · S100A
    Long-term follow-up of Keytruda 3L+ for RCC: KEYNOTE-16
    S. Modi, P. Schmid, C. Saura, et al. · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  112. Abstract LBA4111LBA2026-09-04 · 19:00 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-539
    S. Tolaney, T. Mok, A. Spira · University of Chicago
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  113. Abstract 16342026-09-03 · 20:45 CT · Arie Crown Theater
    MONALEESA-24: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    T. Mok, H. Rugo · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  114. Abstract 46702026-09-02 · 18:00 CT · S406
    Long-term follow-up of Padcev maintenance for urothelial carcinoma: EV-850
    G. Curigliano, M. Reck, H. Rugo, et al. · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  115. Abstract 19042026-09-03 · 13:45 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-818 study)
    G. Curigliano, C. Saura, H. Borghaei · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  116. Abstract 15012026-09-03 · 16:45 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-708 study)
    S. Peters, R. Herbst, M. Krop, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  117. Abstract 92992026-09-01 · 21:45 CT · Arie Crown Theater
    Long-term follow-up of Tecentriq 3L+ for NSCLC: IMpower-496
    H. Borghaei, P. Schmid, C. Robert, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  118. Abstract 98592026-09-03 · 18:00 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-588 study)
    M.C. Garassino, M. Reck, M. Krop, et al. · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  119. Abstract 95662026-09-03 · 14:00 CT · S100A
    Long-term follow-up of Imfinzi 2L for NSCLC: PACIFIC-15
    R. Herbst, J. Cortes, S. Tolaney, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  120. Abstract TPS81192026-09-04 · 18:15 CT · Hall B1
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-603
    M.C. Garassino, J. Brahmer · Dana-Farber Cancer Institute
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  121. Abstract 63822026-09-01 · 20:30 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in RCC
    M.C. Garassino, F. Andre · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  122. Abstract 99042026-09-04 · 16:30 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-153
    T. Mok, L. Paz-Ares · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  123. Abstract 43132026-09-05 · 15:45 CT · E450
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-472 study)
    H. Borghaei, N. Rizvi, E. Winer, et al. · Royal Marsden Hospital
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  124. Abstract 61272026-09-02 · 13:00 CT · E450
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-440
    E. Winer, C. Saura · National Cancer Center Japan
    Poster SessionGynecologic Cancer📄🖼️
  125. Abstract 99442026-09-01 · 21:00 CT · S406
    KEYNOTE-244: Keytruda (pembrolizumab) maintenance in NSCLC
    M.C. Garassino, R. Herbst, H. Rugo · Cleveland Clinic
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  126. Abstract 60022026-09-05 · 21:00 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-246
    C. Saura, S. Peters, P. Schmid, et al. · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  127. Abstract LBA4126LBA2026-09-05 · 18:15 CT · Hall B1
    MONARCH-9: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    E. Winer, L. Paz-Ares, G. Curigliano · Mayo Clinic
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  128. Abstract 19742026-09-03 · 16:15 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-346
    M. Reck, A. Spira · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  129. Abstract 14732026-09-05 · 16:30 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-364
    S. Modi, N. Rizvi, C. Robert, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  130. Abstract 94642026-09-04 · 15:30 CT · Hall B1
    Quality of life outcomes with Tagrisso in patients with NSCLC
    M. Krop, H. Borghaei · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  131. Abstract 52802026-09-04 · 14:45 CT · S100A
    Biomarker subgroup analysis of Lynparza in prostate (the OlympiA-532 study)
    T. Mok, L. Paz-Ares · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  132. Abstract 99432026-09-03 · 18:15 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-462
    M. Reck, P. Schmid · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  133. Abstract 93812026-09-03 · 20:30 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-872
    J. Brahmer, M. Krop · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  134. Abstract 19342026-09-02 · 13:00 CT · Arie Crown Theater
    PALOMA-555: Ibrance (palbociclib) 2L in HR+ breast cancer
    M. Krop, S. Modi · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  135. Abstract 63392026-09-05 · 20:30 CT · S100A
    Long-term follow-up of Lynparza 3L+ for ovarian: OlympiA-124
    P. Schmid, M.C. Garassino, H. Borghaei, et al. · National Cancer Center Japan
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  136. Abstract 67462026-09-03 · 19:15 CT · S406
    Quality of life outcomes with Opdivo in patients with RCC
    M. Reck, G. Curigliano, H. Rugo, et al. · Mayo Clinic
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  137. Abstract 14282026-09-05 · 20:30 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-980
    M. Reck, J. Cortes, J. Brahmer, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  138. Abstract 10742026-09-04 · 18:15 CT · S406
    MONARCH-866: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    T. Mok, J. Brahmer, H. Rugo · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  139. Abstract 13352026-09-04 · 18:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-803 study)
    S. Modi, C. Robert, F. Andre, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  140. Abstract LBA4139LBA2026-09-04 · 14:15 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-113
    S. Tolaney, H. Rugo · National Cancer Center Japan
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  141. Abstract 46742026-09-05 · 16:00 CT · Hall B1
    EV-175: Padcev (enfortumab vedotin) 2L in urothelial carcinoma
    S. Tolaney, J. Brahmer, N. Rizvi, et al. · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  142. Abstract 49562026-09-03 · 15:00 CT · Hall B1
    Long-term follow-up of Padcev 2L for urothelial carcinoma: EV-255
    G. Curigliano, N. Rizvi, S. Tolaney, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  143. Abstract TPS81422026-09-04 · 16:45 CT · E450
    Long-term follow-up of Lynparza adjuvant for HR+ breast cancer: OlympiA-827
    E. Winer, N. Rizvi · Peter MacCallum Cancer Centre
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  144. Abstract 17712026-09-01 · 13:45 CT · E450
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-539
    S. Peters, A. Spira, H. Borghaei · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  145. Abstract 17652026-09-02 · 20:15 CT · E450
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-705
    L. Paz-Ares, C. Saura, J. Brahmer, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  146. Abstract 66712026-09-05 · 15:15 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-408
    M.C. Garassino, S. Tolaney · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  147. Abstract 52532026-09-01 · 13:15 CT · S100A
    Long-term follow-up of Lynparza neoadjuvant for prostate: OlympiA-357
    S. Antonia, S. Peters, M. Krop, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  148. Abstract LBA4147LBA2026-09-02 · 15:30 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-380
    A. Spira, S. Tolaney, J. Brahmer, et al. · Chinese University of Hong Kong
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  149. Abstract 11372026-09-05 · 19:00 CT · S406
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    H. Rugo, M. Krop · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  150. Abstract LBA4149LBA2026-09-01 · 19:45 CT · Arie Crown Theater
    Long-term follow-up of Enhertu maintenance for HR+ breast cancer: DESTINY-Breast-259
    H. Rugo, E. Winer, S. Modi · Princess Margaret Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  151. Abstract 92132026-09-02 · 20:30 CT · S406
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-360 study)
    F. Andre, M. Reck · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  152. Abstract 48932026-09-04 · 13:45 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-123
    J. Brahmer, P. Schmid, N. Rizvi, et al. · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  153. Abstract 98592026-09-01 · 20:00 CT · S100A
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-973
    S. Peters, H. Borghaei, C. Saura, et al. · Royal Marsden Hospital
    Poster SessionMelanoma📄🖼️
  154. Abstract 45422026-09-02 · 18:15 CT · S406
    Opdivo plus chemotherapy in previously untreated HCC: updated analysis from CheckMate-815
    S. Antonia, F. Andre, H. Rugo, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  155. Abstract 95592026-09-03 · 19:00 CT · Arie Crown Theater
    FLAURA-64: Tagrisso (osimertinib) adjuvant in NSCLC
    C. Saura, S. Modi, S. Tolaney, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  156. Abstract 42692026-09-02 · 18:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-607 study)
    F. Andre, P. Schmid, S. Peters, et al. · MD Anderson Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  157. Abstract 13362026-09-05 · 19:45 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-118 study)
    H. Borghaei, S. Antonia, M.C. Garassino, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  158. Abstract 17342026-09-05 · 18:00 CT · S100A
    Long-term follow-up of Lynparza maintenance for HR+ breast cancer: OlympiA-578
    F. Andre, M. Reck, S. Peters · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  159. Abstract 58122026-09-03 · 13:00 CT · Hall B1
    Long-term follow-up of Lynparza maintenance for ovarian: OlympiA-720
    S. Antonia, S. Peters · MD Anderson Cancer Center
    Poster SessionGynecologic Cancer📄🖼️
  160. Abstract 45472026-09-03 · 21:45 CT · S100A
    Real-world effectiveness of Trodelvy vs standard of care in urothelial carcinoma
    R. Herbst, C. Robert, C. Saura, et al. · Karolinska Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  161. Abstract 43012026-09-03 · 18:00 CT · E450
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-155 study)
    P. Schmid, J. Cortes · Cleveland Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  162. Abstract 45412026-09-03 · 19:30 CT · Arie Crown Theater
    Long-term follow-up of Padcev 2L for urothelial carcinoma: EV-533
    M. Reck, S. Antonia, T. Mok, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  163. Abstract 13702026-09-04 · 20:45 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-304 study)
    R. Herbst, F. Andre · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  164. Abstract 47512026-09-03 · 20:15 CT · Hall B1
    EV-192: Padcev (enfortumab vedotin) 3L+ in urothelial carcinoma
    R. Herbst, F. Andre, P. Schmid · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  165. Abstract TPS81642026-09-05 · 15:45 CT · Arie Crown Theater
    CheckMate-843: Opdivo (nivolumab) 2L in NSCLC
    M. Krop, H. Borghaei, E. Winer, et al. · Dana-Farber Cancer Institute
    Trials in Progress Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  166. Abstract 93302026-09-05 · 21:15 CT · E450
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-895
    F. Andre, M.C. Garassino, G. Curigliano, et al. · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  167. Abstract 94932026-09-01 · 21:00 CT · E450
    DESTINY-Breast-472: Enhertu (trastuzumab deruxtecan) maintenance in NSCLC
    S. Antonia, C. Saura · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  168. Abstract e121672026-09-04 · 16:30 CT · E450
    ASCENT-663: Trodelvy (sacituzumab govitecan) 2L in TNBC
    F. Andre, T. Mok · Karolinska Institute
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  169. Abstract 10852026-09-01 · 15:45 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-429 study)
    N. Rizvi, S. Tolaney, P. Schmid, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  170. Abstract 48342026-09-03 · 14:45 CT · S406
    Real-world effectiveness of Enhertu vs standard of care in gastric
    S. Antonia, A. Spira, T. Mok, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  171. Abstract 101262026-09-01 · 19:00 CT · S100A
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    R. Herbst, C. Robert · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  172. Abstract 49242026-09-04 · 16:15 CT · Hall B1
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-280 study)
    S. Modi, R. Herbst, F. Andre · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  173. Abstract 18172026-09-03 · 19:30 CT · E450
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-235
    E. Winer, T. Mok, L. Paz-Ares, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  174. Abstract 12072026-09-05 · 14:00 CT · E450
    PALOMA-965: Ibrance (palbociclib) maintenance in HR+ breast cancer
    H. Rugo, S. Modi · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  175. Abstract 97332026-09-01 · 15:00 CT · Arie Crown Theater
    PACIFIC-526: Imfinzi (durvalumab) neoadjuvant in SCLC
    P. Schmid, R. Herbst, M.C. Garassino · Cleveland Clinic
    Poster SessionLung Cancer—Small Cell📄🖼️
  176. Abstract 10912026-09-01 · 13:30 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-57
    G. Curigliano, C. Saura · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  177. Abstract 92872026-09-04 · 19:45 CT · S100A
    DESTINY-Breast-649: Enhertu (trastuzumab deruxtecan) 1L in NSCLC
    G. Curigliano, J. Brahmer, C. Robert, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  178. Abstract 15862026-09-02 · 14:15 CT · E450
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-4
    M.C. Garassino, F. Andre · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  179. Abstract 97772026-09-03 · 21:45 CT · S100A
    FLAURA-348: Tagrisso (osimertinib) 1L in NSCLC
    M.C. Garassino, P. Schmid · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  180. Abstract 10342026-09-03 · 14:00 CT · S406
    OlympiA-636: Lynparza (olaparib) adjuvant in HR+ breast cancer
    M. Krop, H. Borghaei, S. Antonia, et al. · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  181. Abstract 90562026-09-02 · 19:30 CT · S100A
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-903
    P. Schmid, G. Curigliano, N. Rizvi · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  182. Abstract 95822026-09-02 · 18:15 CT · Arie Crown Theater
    DESTINY-Breast-333: Enhertu (trastuzumab deruxtecan) neoadjuvant in NSCLC
    J. Cortes, M. Krop, F. Andre · Institut Gustave Roussy
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  183. Abstract 59832026-09-05 · 14:45 CT · S100A
    OlympiA-973: Lynparza (olaparib) 2L in prostate
    H. Rugo, S. Peters · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  184. Abstract 15272026-09-05 · 19:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-767
    C. Saura, S. Tolaney · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  185. Abstract 17322026-09-05 · 18:45 CT · E450
    PALOMA-464: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    T. Mok, J. Cortes, S. Antonia, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  186. Abstract 13092026-09-01 · 21:00 CT · Hall B1
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-332
    A. Spira, P. Schmid · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  187. Abstract 93962026-09-01 · 20:30 CT · Hall B1
    Long-term follow-up of Enhertu adjuvant for NSCLC: DESTINY-Breast-175
    M.C. Garassino, M. Krop, R. Herbst · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  188. Abstract 13312026-09-03 · 16:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-946 study)
    C. Saura, S. Antonia · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  189. Abstract 16212026-09-04 · 13:00 CT · Arie Crown Theater
    Long-term follow-up of Enhertu neoadjuvant for HR+ breast cancer: DESTINY-Breast-491
    H. Rugo, S. Antonia · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  190. Abstract 99372026-09-01 · 14:30 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-790
    S. Modi, H. Rugo, J. Brahmer · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  191. Abstract LBA4190LBA2026-09-02 · 21:15 CT · S100A
    Long-term follow-up of Keytruda 3L+ for metastatic melanoma: KEYNOTE-182
    E. Winer, R. Herbst, G. Curigliano · Massachusetts General Hospital
    Late-Breaking Oral Abstract SessionMelanoma📄🖼️🎬
  192. Abstract 92622026-09-05 · 13:00 CT · Hall B1
    Long-term follow-up of Keytruda 2L for SCLC: KEYNOTE-280
    H. Borghaei, S. Modi · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  193. Abstract TPS81922026-09-02 · 16:00 CT · S406
    PACIFIC-759: Imfinzi (durvalumab) 2L in NSCLC
    E. Winer, P. Schmid, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Trials in Progress Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  194. Abstract e121932026-09-02 · 14:15 CT · Arie Crown Theater
    Quality of life outcomes with Imfinzi in patients with SCLC
    M. Reck, H. Rugo, H. Borghaei, et al. · Institut Gustave Roussy
    Publication OnlyLung Cancer—Small Cell📄🖼️
  195. Abstract 18542026-09-05 · 19:30 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-237 study)
    S. Modi, H. Rugo, R. Herbst · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  196. Abstract 16142026-09-03 · 16:45 CT · S100A
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-520
    R. Herbst, S. Peters · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  197. Abstract 48262026-09-02 · 20:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-907 study)
    E. Winer, H. Rugo, J. Brahmer · Dana-Farber Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  198. Abstract 12222026-09-01 · 18:45 CT · E450
    PALOMA-623: Ibrance (palbociclib) maintenance in HR+ breast cancer
    C. Saura, P. Schmid, H. Borghaei, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  199. Abstract 16102026-09-03 · 18:15 CT · S100A
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-591
    G. Curigliano, J. Brahmer, S. Modi · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  200. Abstract 12202026-09-04 · 19:45 CT · Hall B1
    MONALEESA-556: Kisqali (ribociclib) maintenance in HR+ breast cancer
    A. Spira, E. Winer, F. Andre, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.